Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 46.49% is 80% below its 1-year average of 233.14%, near the low end of its 1-year range (-88.89%–1098.52%).
80.06% below its 12-month average of 233.14%.
Reported quarterly gross margin; no daily interpolation. Q3 FY2026 (2026-06-30): -88.89%.
GROSS MARGIN
46.49%
GROSS MARGIN AVG TTM
233.14%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-80.06%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+12.35%
vs the sector median at left
Outlook Therapeutics, Inc.
Market Cap
$107.00M
Gross Margin
46.49%
TTM Avg
233.14%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$106.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$106.98M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$106.44M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.35%
Market Cap
$108.43M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$109.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$104.37M
Gross Margin
71.67%
TTM Avg
77.09%
3Y Avg
79.04%
5Y Avg
77.65%
Market Cap
$109.79M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | $107.00M | 46.49% | 233.14% | 0.00% | 0.00% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 83.37% | 83.81% | 82.64% | 80.50% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.44M | 0.00% | 0.00% | 0.00% | 2.35% |
| Immunic, Inc. (IMUX)vs › | $105.70M | 0.00% | 0.00% | 0.00% | 0.00% |
| Apyx Medical Corporation (APYX)vs › | $108.43M | 33.94% | 48.53% | 56.75% | 59.91% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Definitive Healthcare Corp. (DH)vs › | $104.37M | 71.67% | 77.09% | 79.04% | 77.65% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.79M | 11.17% | 22.02% | 17.41% | 13.61% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.18M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
46.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -88.89% |
| 2026-03-31 | -17.18% |
| 2025-12-31 | 102.45% |
| 2025-09-30 | 1098.52% |
| 2025-06-30 | 70.78% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 47.87% |
| 2017-09-30 | 20.57% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
